M. Naesens, D. R. Kuypers, and M. Sarwal, Calcineurin inhibitor nephrotoxicity, Clinical journal of the American Society of Nephrology : CJASN, vol.4, issue.2, pp.481-508, 2009.
DOI : 10.2215/cjn.04800908

URL : https://cjasn.asnjournals.org/content/4/2/481.full.pdf

R. S. Gaston, Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm, Clinical journal of the American Society of Nephrology : CJASN, vol.4, issue.12, pp.2029-2063, 2009.
DOI : 10.2215/cjn.03820609

URL : https://cjasn.asnjournals.org/content/4/12/2029.full.pdf

A. J. Matas, Chronic progressive calcineurin nephrotoxicity: an overstated concept, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.11, issue.4, pp.687-92, 2011.
DOI : 10.1111/j.1600-6143.2011.03505.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-6143.2011.03505.x

G. Einecke, B. Sis, and J. Reeve, Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.9, issue.11, pp.2520-2551, 2009.

R. S. Gaston, J. M. Cecka, and B. L. Kasiske, Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure, Transplantation, vol.90, issue.1, pp.68-74, 2010.

A. Loupy, G. S. Hill, and S. C. Jordan, The impact of donor-specific anti-HLA antibodies on late kidney allograft failure, Nat Rev Nephrol, vol.8, issue.6, pp.348-57, 2012.

S. Gourishankar, R. Leduc, and J. Connett, Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.10, issue.2, pp.324-354, 2010.

J. Bamoulid, O. Staeck, and F. Halleck, The need for minimization strategies: current problems of immunosuppression. Transplant international : official journal of the European Society for, Organ Transplantation, vol.28, issue.8, pp.891-900, 2015.

R. Prashar and K. K. Venkat, Immunosuppression minimization and avoidance protocols: when less is not more, Adv Chronic Kidney Dis, vol.23, issue.5, pp.295-300, 2016.
DOI : 10.1053/j.ackd.2016.09.007

A. Sharif, S. Shabir, S. Chand, P. Cockwell, S. Ball et al., Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation, Journal of the American Society of Nephrology : JASN, vol.22, issue.11, pp.2107-2125, 2011.

J. Moore, L. Middleton, and P. Cockwell, Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and metaanalysis, Transplantation, vol.87, issue.4, pp.591-605, 2009.

D. Sawinski, J. Trofe-clark, and B. Leas, Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.16, issue.7, pp.2117-2155, 2016.

, Clinical Guidelines for Transpant Medications, 2018.

J. Schiff, E. Cole, and M. Cantarovich, Therapeutic monitoring of calcineurin inhibitors for the nephrologist, Clinical journal of the American Society of Nephrology : CJASN, vol.2, issue.2, pp.374-84, 2007.

P. Wallemacq, V. W. Armstrong, and M. Brunet, Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference, Ther Drug Monit, vol.31, issue.2, pp.139-52, 2009.

M. A. Beland, I. Lapointe, and R. Noel, Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study. Transplant international : official journal of the European Society for Organ Transplantation, vol.30, pp.502-511, 2017.

N. Shuker, T. Van-gelder, and D. A. Hesselink, Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management, Transplant Rev (Orlando), vol.29, issue.2, pp.78-84, 2015.

K. M. Karpe, G. S. Talaulikar, and G. D. Walters, Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients, Cochrane Database Syst Rev, vol.7, p.6750, 2017.

C. Lefaucheur, A. Loupy, and G. S. Hill, Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation, Journal of the American Society of Nephrology : JASN, vol.21, issue.8, pp.1398-406, 2010.

S. Mohan, A. Palanisamy, and D. Tsapepas, Donor-specific antibodies adversely affect kidney allograft outcomes, Journal of the American Society of Nephrology : JASN, vol.23, issue.12, pp.2061-71, 2012.

A. A. Vo, A. Peng, and M. Toyoda, Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation, Transplantation, vol.89, issue.9, pp.1095-102, 2010.

L. G. Hidalgo, P. M. Campbell, and B. Sis, De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.9, issue.11, pp.2532-2573, 2009.

R. L. Heilman, A. Nijim, and Y. M. Desmarteau, De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation, Transplantation, vol.98, issue.12, pp.1310-1315, 2014.

J. E. Cooper, J. Gralla, L. Cagle, R. Goldberg, L. Chan et al., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes, Transplantation, vol.91, issue.10, pp.1103-1112, 2011.

J. M. Devos, A. O. Gaber, and L. D. Teeter, Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection, Transplantation, vol.97, issue.5, pp.534-574, 2014.

C. Wiebe, I. W. Gibson, and T. D. Blydt-hansen, Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.12, issue.5, pp.1157-67, 2012.

F. Moreso, M. Ibernon, and M. Goma, Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.6, issue.4, pp.747-52, 2006.

F. Moreso, M. Carrera, and M. Goma, Early subclinical rejection as a risk factor for late chronic humoral rejection, Transplantation, vol.93, issue.1, pp.41-47, 2012.

P. Gatault, N. Kamar, and M. Buchler, Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.17, issue.5, pp.1370-1379, 2017.

E. Dugast, J. P. Soulillou, and Y. Foucher, Failure of Calcineurin inhibitor (tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.16, issue.11, pp.3255-61, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150143

, KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol.9, issue.3, pp.1-155, 2009.

R. Ferguson, J. Grinyo, and F. Vincenti, Immunosuppression with belataceptbased, corticosteroid-avoiding regimens in de novo kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.11, issue.1, pp.66-76, 2011.

P. Bolin, F. S. Shihab, and L. Mulloy, Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results, Transplantation, vol.86, issue.1, pp.88-95, 2008.

H. Ekberg, H. Tedesco-silva, and A. Demirbas, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, vol.357, issue.25, pp.2562-75, 2007.

N. Kamar, L. Rostaing, and E. Cassuto, A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients, Clin Nephrol, vol.77, issue.2, pp.126-162, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00723074

R. Bouamar, N. Shuker, and D. A. Hesselink, Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(dagger), Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.13, issue.5, pp.1253-61, 2013.

T. Van-gelder, H. T. Silva, and J. W. De-fijter, Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial, Transplantation, vol.86, issue.8, pp.1043-51, 2008.

R. S. Gaston, B. Kaplan, and T. Shah, Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.9, issue.7, pp.1607-1626, 2009.

J. J. Gaynor, G. Ciancio, and G. Guerra, Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transplant international : official journal of the European Society for, Organ Transplantation, vol.29, issue.2, pp.216-242, 2016.

G. Ciancio, G. W. Burke, and J. J. Gaynor, A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year, Transplantation, vol.77, issue.2, pp.252-260, 2004.

G. Ciancio, G. W. Burke, and J. J. Gaynor, A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring, Transplantation, vol.80, issue.4, pp.457-65, 2005.

G. Ciancio, J. J. Gaynor, and D. Roth, Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation, Transplant Proc, vol.42, issue.9, pp.3503-3509, 2010.

G. Ciancio, G. W. Burke, and J. J. Gaynor, Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up, Transplantation, vol.86, issue.1, pp.67-74, 2008.

J. M. Neuberger, W. O. Bechstein, and D. R. Kuypers, Practical recommendations for long-term Management of Modifiable Risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group, Transplantation, vol.101, issue.4S, pp.1-56, 2017.

I. Ferrandiz, C. , N. , D. Bello, and A. , Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.16, issue.9, pp.2661-2670, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02149473

R. A. Bray, H. M. Gebel, and R. Townsend, De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

, Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg, vol.18, issue.7, pp.1783-1792, 2018.

J. Pascual, S. P. Berger, and O. Witzke, Everolimus with reduced Calcineurin inhibitor exposure in renal transplantation, Journal of the American Society of Nephrology : JASN, vol.29, issue.7, pp.1979-91, 2018.

C. Sommerer, B. Suwelack, and D. Dragun, Design and rationale of the ATHENA study--a 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial, Trials, vol.17, p.92, 2016.